Ovid Therapeutics (OVID) Stock Forecast, Price Target & Predictions
OVID Stock Forecast
Ovid Therapeutics stock forecast is as follows: an average price target of $3.00 (represents a 200.27% upside from OVID’s last price of $1.00) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
OVID Price Target
The average price target for Ovid Therapeutics (OVID) is $3.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 200.27% upside from OVID's last price of $1.00.
OVID Analyst Ratings
According to 5 Wall Street analysts, Ovid Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for OVID stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ovid Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 02, 2024 | Raghuram Selvaraju | H.C. Wainwright | $3.00 | $0.86 | 247.95% | 200.27% |
| May 20, 2024 | Thomas Shrader | BTIG | $11.00 | $3.14 | 250.32% | 1000.99% |
| May 14, 2024 | Francois Brisebois | Oppenheimer | $8.00 | $3.23 | 147.68% | 700.72% |
The latest Ovid Therapeutics stock forecast, released on Jul 02, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $3.00, which represents a 247.95% increase from the stock price at the time of the forecast ($0.86), and a 200.27% increase from OVID last price ($1.00).
Ovid Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $7.33 |
| Last Closing Price | $1.00 | $1.00 | $1.00 |
| Upside/Downside | -100.00% | -100.00% | 633.66% |
In the current month, the average price target of Ovid Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ovid Therapeutics's last price of $1.00. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 19, 2024 | Citigroup | Underperform | Underperform | Hold |
| Aug 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 26, 2024 | Citigroup | Underperform | Underperform | Hold |
| Jul 26, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 18, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 18, 2024 | B. Riley | Buy | Buy | Hold |
| Jun 18, 2024 | Wedbush | Buy | Buy | Hold |
| Jun 18, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 18, 2024 | Oppenheimer | Outperform | Perform | Downgrade |
| Jun 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 18, 2024 | BTIG | Buy | Buy | Hold |
| Jun 17, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 20, 2024 | BTIG | Buy | Buy | Hold |
| May 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 07, 2024 | Citigroup | Neutral | Neutral | Hold |
| Apr 30, 2024 | B. Riley | Buy | Initialise | |
| Apr 04, 2024 | Wedbush | Outperform | Initialise |
Ovid Therapeutics's last stock rating was published by Citigroup on Aug 19, 2024. The company gave OVID a "Underperform" rating, the same as its previous rate.
Ovid Therapeutics Financial Forecast
Ovid Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $108.97M | $75.00M | $66.16K | $1.45M | $208.38M | $5.70M | $6.91M |
| Avg Forecast | $8.70M | $23.00K | $8.75M | $73.00K | $99.33K | $107.67K | $8.82M | $124.33K | $190.38K | $105.50K | $65.38K | $52.08K | $8.62M | $45.83K | $47.75K | $18.77K | $1.31M | $100.53M | $4.16M | $100.00K |
| High Forecast | $8.70M | $23.00K | $8.75M | $73.00K | $99.33K | $107.67K | $8.82M | $124.33K | $261.76K | $105.50K | $65.56K | $52.08K | $11.20M | $45.83K | $47.75K | $18.77K | $1.57M | $100.53M | $4.16M | $100.00K |
| Low Forecast | $8.70M | $23.00K | $8.75M | $73.00K | $99.33K | $107.67K | $8.82M | $124.33K | $118.98K | $105.50K | $65.19K | $52.08K | $6.89M | $45.83K | $47.75K | $18.77K | $1.05M | $100.53M | $4.16M | $100.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 8 | 4 | 5 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2377.59% | 1570.68% | 3.53% | 1.11% | 2.07% | 1.37% | 69.14% |
Ovid Therapeutics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $8.62M, with a low forecast of $6.89M, and a high forecast of $11.20M. OVID's average Quarter revenue forecast represents a -92.09% decrease compared to the company's last Quarter revenue of $108.97M (Sep 23).
Ovid Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 8 | 4 | 5 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-12.03B | $-14.17B | $-14.89M | $-16.19M | $176.58M | $-21.95M | $-16.35M |
| Avg Forecast | $-2.44M | $-6.45K | $-2.45M | $-20.48K | $-27.87K | $-30.21K | $-2.47M | $-34.89K | $-53.42K | $-29.60K | $-18.34K | $-14.61K | $-2.42M | $-12.86K | $-13.40K | $-5.27K | $-14.46M | $95.96M | $-1.17M | $-28.05K |
| High Forecast | $-2.44M | $-6.45K | $-2.45M | $-20.48K | $-27.87K | $-30.21K | $-2.47M | $-34.89K | $-33.39K | $-29.60K | $-18.29K | $-14.61K | $-1.93M | $-12.86K | $-13.40K | $-5.27K | $-11.57M | $115.16M | $-1.17M | $-28.05K |
| Low Forecast | $-2.44M | $-6.45K | $-2.45M | $-20.48K | $-27.87K | $-30.21K | $-2.47M | $-34.89K | $-73.45K | $-29.60K | $-18.40K | $-14.61K | $-3.14M | $-12.86K | $-13.40K | $-5.27K | $-17.35M | $76.77M | $-1.17M | $-28.05K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 935367.96% | 1057768.47% | 2828.01% | 1.12% | 1.84% | 18.78% | 582.64% |
8 analysts predict OVID's average Quarter EBITDA for Mar 22 to be $-14.46M, with a high of $-11.57M and a low of $-17.35M. This is -108.19% lower than Ovid Therapeutics's previous annual EBITDA (Mar 21) of $176.58M.
Ovid Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 8 | 4 | 5 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-11.25B | $-12.41B | $1.52B | $-16.11M | $176.01M | $-22.03M | $-16.42M |
| Avg Forecast | $447.15K | $-8.43M | $397.46K | $-7.84M | $-11.15M | $-11.02M | $-4.69M | $-10.91M | $-11.97M | $-14.66M | $-15.89M | $-15.86M | $-3.58M | $-13.16M | $-14.50M | $-12.15M | $-14.57M | $95.65M | $-21.67M | $-24.85M |
| High Forecast | $447.15K | $-8.43M | $397.46K | $-7.84M | $-11.15M | $-11.02M | $-4.69M | $-9.46M | $-11.22M | $-14.66M | $-15.89M | $-15.86M | $-3.37M | $-13.16M | $-14.50M | $-12.15M | $-11.66M | $114.78M | $-21.67M | $-24.85M |
| Low Forecast | $447.15K | $-8.43M | $397.46K | $-7.84M | $-11.15M | $-11.02M | $-4.69M | $-11.64M | $-12.72M | $-14.66M | $-15.89M | $-15.86M | $-3.58M | $-13.16M | $-14.50M | $-12.15M | $-17.49M | $76.52M | $-21.67M | $-24.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 854.93% | 855.85% | -125.33% | 1.11% | 1.84% | 1.02% | 0.66% |
Ovid Therapeutics's average Quarter net income forecast for Jun 23 is $-14.50M, with a range of $-14.50M to $-14.50M. OVID's average Quarter net income forecast represents a -100.95% decrease compared to the company's last Quarter net income of $1.52B (Mar 23).
Ovid Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 8 | 4 | 5 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.81B | $8.25B | $8.34M | $9.88M | $15.58M | $10.41M | $7.44M |
| Avg Forecast | $181.87M | $480.93K | $182.92M | $1.53M | $2.08M | $2.25M | $184.34M | $2.60M | $3.98M | $2.21M | $1.37M | $1.09M | $180.15M | $958.36K | $998.45K | $392.42K | $26.56M | $8.47M | $84.57M | $2.03M |
| High Forecast | $181.87M | $480.93K | $182.92M | $1.53M | $2.08M | $2.25M | $184.34M | $2.60M | $5.47M | $2.21M | $1.37M | $1.09M | $234.20M | $958.36K | $998.45K | $392.42K | $31.87M | $10.16M | $84.57M | $2.03M |
| Low Forecast | $181.87M | $480.93K | $182.92M | $1.53M | $2.08M | $2.25M | $184.34M | $2.60M | $2.49M | $2.21M | $1.36M | $1.09M | $144.12M | $958.36K | $998.45K | $392.42K | $21.25M | $6.77M | $84.57M | $2.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 7100.88% | 8261.05% | 21.26% | 0.37% | 1.84% | 0.12% | 3.66% |
Ovid Therapeutics's average Quarter SG&A projection for Dec 23 is $180.15M, based on 4 Wall Street analysts, with a range of $144.12M to $234.20M. The forecast indicates a -97.35% fall compared to OVID last annual SG&A of $6.81B (Sep 23).
Ovid Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 8 | 4 | 5 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-159.34 | $-0.18 | $21.60 | $-0.23 | $2.55 | $-0.34 | $-0.28 |
| Avg Forecast | $0.01 | $-0.12 | $0.01 | $-0.11 | $-0.16 | $-0.16 | $-0.07 | $-0.15 | $-0.17 | $-0.21 | $-0.22 | $-0.22 | $-0.05 | $-0.19 | $-0.20 | $-0.17 | $-0.21 | $1.45 | $-0.31 | $-0.35 |
| High Forecast | $0.01 | $-0.12 | $0.01 | $-0.11 | $-0.16 | $-0.16 | $-0.07 | $-0.13 | $-0.16 | $-0.21 | $-0.22 | $-0.22 | $-0.05 | $-0.19 | $-0.20 | $-0.17 | $-0.21 | $1.45 | $-0.31 | $-0.35 |
| Low Forecast | $0.01 | $-0.12 | $0.01 | $-0.11 | $-0.16 | $-0.16 | $-0.07 | $-0.16 | $-0.18 | $-0.21 | $-0.22 | $-0.22 | $-0.05 | $-0.19 | $-0.20 | $-0.17 | $-0.21 | $1.45 | $-0.31 | $-0.35 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 859.25% | 0.88% | -126.18% | 1.11% | 1.76% | 1.11% | 0.80% |
According to 2 Wall Street analysts, Ovid Therapeutics's projected average Quarter EPS for Jun 23 is $-0.20, with a low estimate of $-0.20 and a high estimate of $-0.20. This represents a -100.95% decrease compared to OVID previous annual EPS of $21.60 (Mar 23).
Ovid Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.04 | $10.00 | 861.54% | Buy |
| TIL | Instil Bio | $21.69 | $150.00 | 591.56% | Hold |
| NXTC | NextCure | $0.90 | $3.00 | 233.33% | Buy |
| CTMX | CytomX Therapeutics | $1.13 | $3.47 | 207.08% | Buy |
| OVID | Ovid Therapeutics | $1.06 | $3.00 | 183.02% | Buy |
| NUVB | Nuvation Bio | $2.81 | $7.00 | 149.11% | Buy |
| ASMB | Assembly Biosciences | $14.28 | $35.50 | 148.60% | Buy |
| ACHL | Achilles Therapeutics | $0.97 | $2.00 | 106.19% | Buy |
| CNTB | Connect Biopharma | $1.06 | $1.50 | 41.51% | Buy |